减少大手术后中重度急性肾损伤的预防性护理策略(BigpAK-2):一项跨国随机临床试验
BigpAK-2是一项在欧洲34家医院开展的多中心随机临床试验,纳入1180例经临床危险因素和肾小管应激生物标志物识别的高危大手术患者。预防性护理策略组中重度急性肾损伤发生率为14.4%,对照组为22.3%(OR 0.57,95%CI 0.40-0.79,P=0.0002)。两组不良事件无差异。
要点
- 高危大手术患者中,预防性护理策略使中重度急性肾损伤发生率从22.3%降至14.4%。
- 需治疗人数为12(95%CI 7-33),即每治疗12例可预防1例中重度急性肾损伤。
- 两组不良事件发生率无差异。
核心结论
- 在高危大手术成人患者中,由支持性措施和避免肾毒性药物组成的预防性护理策略显著减少中重度急性肾损伤的发生,且不增加不良事件。
研究设计与样本
- BigpAK-2为在欧洲34家医院开展的多中心随机临床试验,纳入年龄≥18岁、经预设临床危险因素和肾小管应激生物标志物识别为急性肾损伤高危的大手术患者。
- 患者随机分配至常规护理组或预防性护理策略组,预防性护理策略依据肾脏病改善全球结局指南推荐,包括先进血流动力学监测、容量状态与血流动力学优化、避免肾毒性药物和放射性对比剂、预防高血糖。
- 主要结局为术后72小时内中重度急性肾损伤的发生,在意向治疗人群中评估;安全性通过比较两组不良事件发生率评估。
- 2020年11月25日至2024年6月21日筛查7873例患者,1180例(15.0%)被随机分配(干预组589例[49.9%],对照组591例[50.1%])。
- 1176例患者可用于主要终点分析。
主要发现
- 干预组84例(14.4%)发生中重度急性肾损伤,对照组131例(22.3%)发生(OR 0.57,95%CI 0.40-0.79,P=0.0002;需治疗人数12,95%CI 7-33)。
- 两组不良事件无差异。
- 最常见不良事件为心房颤动(干预组50例[8.8%] vs 对照组56例[9.7%])、血流动力学相关心律失常(干预组41例[7.2%] vs 对照组50例[8.6%])、显著出血或出血(干预组34例[6.0%] vs 对照组31例[5.3%])及非计划重返手术室(干预组29例[5.1%] vs 对照组38例[6.5%])。
关键数值与推荐
- 预防性护理策略依据肾脏病改善全球结局指南推荐:先进血流动力学监测、容量状态与血流动力学优化、避免肾毒性药物和放射性对比剂、预防高血糖。
- 主要结局为术后72小时内中重度急性肾损伤的发生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery. METHODS: BigpAK-2 was a multicentre randomised clinical trial done in 34 hospitals in Europe. Patients (aged ≥18 years) undergoing major surgery at high risk for AKI identified by predefined clinical risk factors and tubular stress biomarkers were randomly assigned to usual care or a preventive care strategy as per recommendations by the Kidney Disease Improving Global Outcome guidelines: advanced hemodynamic monitoring, optimisation of volume status and haemodynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia. The primary outcome was the occurrence of moderate or severe AKI within 72 h after surgery, assessed in the intention-to-treat population. Safety was assessed by comparing rates of adverse events between groups. This trial is registered with ClinicalTrials.gov, NCT04647396. FINDINGS: From Nov 25, 2020, to June 21, 2024, 7873 patients were screened and 1180 (15·0%) were randomly assigned (589 [49·9%] to the intervention group and 591 [50·1%] to the control group). Among the 1176 patients available for the primary endpoint analysis, moderate or severe AKI occurred in 84 (14·4%) patients in the intervention group and in 131 (22·3%) patients in the control group (odds ratio 0·57 [95% CI 0·40-0·79; p=0·0002; number needed to treat 12 [7-33]). There were no differences in adverse events. The most common adverse events were atrial fibrillation (50 [8·8%] in the intervention group vs 56 (9·7%) in the control group), hemodynamically relevant arrhythmias (41 [7·2%] in the intervention group vs 50 [8·6%] in the control group), significant bleeding or haemorrhage (34 [6·0%] in the intervention group vs 31 [5·3%] in the control group), and unplanned return to the operating room (29 [5·1%] in the intervention vs 38 [6·5%] in the control group). INTERPRETATION: Among adults at high risk for AKI undergoing major surgery, a preventive care strategy consisting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of moderate or severe AKI without increasing adverse events. FUNDING: BioMérieux.
引用
- Zarbock A, Ostermann M, Forni L, et al. A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial. Lancet. 2025. PMID: 41242333. doi:10.1016/S0140-6736(25)01717-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。